591 related articles for article (PubMed ID: 29320480)
1. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.
Sulli G; Rommel A; Wang X; Kolar MJ; Puca F; Saghatelian A; Plikus MV; Verma IM; Panda S
Nature; 2018 Jan; 553(7688):351-355. PubMed ID: 29320480
[TBL] [Abstract][Full Text] [Related]
2. The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock.
Ishimaru K; Nakajima S; Yu G; Nakamura Y; Nakao A
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847374
[TBL] [Abstract][Full Text] [Related]
3. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy.
Shen W; Zhang W; Ye W; Wang H; Zhang Q; Shen J; Hong Q; Li X; Wen G; Wei T; Zhang J
Theranostics; 2020; 10(10):4466-4480. PubMed ID: 32292508
[No Abstract] [Full Text] [Related]
4. Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.
Amador A; Huitron-Resendiz S; Roberts AJ; Kamenecka TM; Solt LA; Burris TP
PLoS One; 2016; 11(9):e0162452. PubMed ID: 27603791
[TBL] [Abstract][Full Text] [Related]
5. REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009.
Amador A; Kamenecka TM; Solt LA; Burris TP
Biochem Pharmacol; 2018 Apr; 150():1-8. PubMed ID: 29355503
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological modulation and genetic deletion of REV-ERBα and REV-ERBβ regulates dendritic cell development.
Amir M; Campbell S; Kamenecka TM; Solt LA
Biochem Biophys Res Commun; 2020 Jul; 527(4):1000-1007. PubMed ID: 32439175
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.
Amador A; Wang Y; Banerjee S; Kameneka TM; Solt LA; Burris TP
PLoS One; 2016; 11(3):e0151014. PubMed ID: 26963516
[TBL] [Abstract][Full Text] [Related]
8. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
[TBL] [Abstract][Full Text] [Related]
9. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.
Dierickx P; Emmett MJ; Jiang C; Uehara K; Liu M; Adlanmerini M; Lazar MA
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12147-12152. PubMed ID: 31127047
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of nuclear receptor REV-ERBs suppresses production of pronociceptive molecules in cultured spinal astrocytes and ameliorates mechanical hypersensitivity of inflammatory and neuropathic pain of mice.
Morioka N; Kodama K; Tomori M; Yoshikawa K; Saeki M; Nakamura Y; Zhang FF; Hisaoka-Nakashima K; Nakata Y
Brain Behav Immun; 2019 May; 78():116-130. PubMed ID: 30682503
[TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells.
Wang Y; Kojetin D; Burris TP
Biochem Pharmacol; 2015 Aug; 96(4):315-22. PubMed ID: 26074263
[TBL] [Abstract][Full Text] [Related]
12. REV-ERBα and REV-ERBβ function as key factors regulating Mammalian Circadian Output.
Ikeda R; Tsuchiya Y; Koike N; Umemura Y; Inokawa H; Ono R; Inoue M; Sasawaki Y; Grieten T; Okubo N; Ikoma K; Fujiwara H; Kubo T; Yagita K
Sci Rep; 2019 Jul; 9(1):10171. PubMed ID: 31308426
[TBL] [Abstract][Full Text] [Related]
13. Rev-erb agonist and TGF-β similarly affect autophagy but differentially regulate hepatic stellate cell fibrogenic phenotype.
Thomes PG; Brandon-Warner E; Li T; Donohue TM; Schrum LW
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):137-147. PubMed ID: 27840152
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological activation of REV-ERBα represses LPS-induced microglial activation through the NF-κB pathway.
Guo DK; Zhu Y; Sun HY; Xu XY; Zhang S; Hao ZB; Wang GH; Mu CC; Ren HG
Acta Pharmacol Sin; 2019 Jan; 40(1):26-34. PubMed ID: 29950615
[TBL] [Abstract][Full Text] [Related]
15. Circadian Clock REV-ERBs Agonist SR9009 Induces Synergistic Antitumor Activity in Multiple Myeloma by Suppressing Glucose-Regulated Protein 78-Dependent Autophagy and Lipogenesis.
Wang R; Liu SL; Guo QQ; Shi XH; Ma MM
World J Oncol; 2023 Dec; 14(6):464-475. PubMed ID: 38022411
[TBL] [Abstract][Full Text] [Related]
16. REV-ERB Agonist SR9009 Regulates the Proliferation and Neurite Outgrowth/Suppression of Cultured Rat Adult Hippocampal Neural Stem/Progenitor Cells in a Concentration-Dependent Manner.
Shimozaki K
Cell Mol Neurobiol; 2022 Aug; 42(6):1765-1776. PubMed ID: 33599915
[TBL] [Abstract][Full Text] [Related]
17. REV-ERB agonist suppresses IL-17 production in γδT cells and improves psoriatic dermatitis in a mouse model.
Wang S; Kozai M; Mita H; Cai Z; Masum MA; Ichii O; Takada K; Inaba M
Biomed Pharmacother; 2021 Dec; 144():112283. PubMed ID: 34628169
[TBL] [Abstract][Full Text] [Related]
18. Circadian clock: Time for novel anticancer strategies?
Ercolani L; Ferrari A; De Mei C; Parodi C; Wade M; Grimaldi B
Pharmacol Res; 2015 Oct; 100():288-95. PubMed ID: 26319800
[TBL] [Abstract][Full Text] [Related]
19. REV-ERBs negatively regulate mineralization of the cementoblasts.
Fu L; Wang M; Zhu G; Zhao Z; Sun H; Cao Z; Xia H
Biochem Biophys Res Commun; 2022 Jan; 587():9-15. PubMed ID: 34861472
[TBL] [Abstract][Full Text] [Related]
20. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs.
Xu H; Zhang J; Zheng X; Tan P; Xiong X; Yi X; Yang Y; Wang Y; Liao D; Li H; Wei Q; Ai J; Yang L
Cell Death Dis; 2022 Nov; 13(11):949. PubMed ID: 36357378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
